Page last updated: 2024-12-06
tiflucarbine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
tiflucarbine: structure given in first source; calmodulin antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 65677 |
| CHEMBL ID | 2104715 |
| SCHEMBL ID | 500036 |
| MeSH ID | M0143660 |
Synonyms (18)
| Synonym |
|---|
| tiflucarbine |
| CHEMBL2104715 |
| tiflucarbinum [latin] |
| 6h-pyrido(4,3-b)thieno(3,2-e)indole, 9-ethyl-4-fluoro-7,8,9,10-tetrahydro-1-methyl- |
| 9-ethyl-4-fluoro-7,8,9,10-tetrahydro-1-methyl-6h-pyrido(4,3-b)thieno(3,2-e)indole |
| tiflucarbina [spanish] |
| 89875-86-5 |
| tiflucarbina |
| m2108nuy0c , |
| unii-m2108nuy0c |
| tiflucarbine [inn] |
| tiflucarbinum |
| SCHEMBL500036 |
| DTXSID90237924 |
| bay-p 4495 |
| Q27283371 |
| 14-ethyl-7-fluoro-3-methyl-5-thia-10,14-diazatetracyclo[7.7.0.02,6.011,16]hexadeca-1,3,6,8,11(16)-pentaene |
| bay- 4495 |
Research Excerpts
Overview
Tiflucarbine is a structurally novel antidepressant that binds at central serotonin (5-HT) binding sites.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Tiflucarbine is a structurally novel antidepressant that binds at central serotonin (5-HT) binding sites. " | ( Stimulus properties of tiflucarbine: a novel antidepressant agent. De Vry, J; Glaser, T; Glennon, RA; Spencer, DG, 1990) | 2.03 |
Treatment
| Excerpt | Reference | Relevance |
|---|---|---|
| "Tiflucarbine treatment increased the specific activity of soluble calmodulin (CaM)-dependent phosphodiesterase in rat brain." | ( The potential antidepressant tiflucarbine down-regulates beta-adrenoceptors in rat brain. Schmidt, BH; Schultz, JE, 1986) | 1.28 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 5 (83.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||